MK-677 Stacking and Combinations
Which compounds MK-677 is paired with, and the rationale behind each combination.
MK-677 + CJC-1295 (no-DAC)
A common research pairing that combines MK-677's sustained, 24-hour ghrelin-receptor activation with a GHRH analog's direct stimulation of the pituitary's own GH-releasing pathway. The two act on distinct receptor systems (GHSR-1a vs GHRH-receptor), which is the typical rationale researchers cite for combining a secretagogue with a GHRH analog rather than stacking two secretagogues. No clinical trial has tested this specific combination directly; the rationale is mechanistic, extrapolated from each compound's individual pharmacology.
MK-677 + Ipamorelin
Because both compounds act at the same receptor (GHSR-1a), this pairing is mechanistically redundant rather than synergistic — MK-677 already keeps the receptor engaged around the clock, so adding a short-acting GHRP on top does not add a distinct pathway the way a GHRH analog does. Researchers who want an oral-only protocol sometimes use MK-677 alone rather than combining it with an injectable in the same GHSR-1a class.
Commonly paired with
- CJC-1295 (no-DAC) — The short-acting form of CJC-1295 (Mod GRF 1-29): a sharp, pulsatile GH release that closely mimics natural rhythm.
- Ipamorelin — A selective GH secretagogue (ghrelin mimetic) that raises growth hormone with minimal effect on cortisol or appetite.
References
- MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. · Murphy MG, Plunkett LM, Gertz BJ, He W, Wittreich J, Polvino WM, Clemmons DR · 1998
- Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. · Nass R, Pezzoli SS, Oliveri MC, Patrie J, Harman SM, Carlson OD, Egan JM, Evans WS, Veldhuis JD, Thorner MO · 2008
- Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group. · Murphy MG, Bach MA, Plotkin D, Bolognese J, Ng J, Krupa D, Cerchio K, Gertz BJ · 1999
- Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. · Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ · 2001
- Ibutamoren | C27H36N4O5S | CID 9576836 - PubChem - NIH